Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2012

View Archived Issues

Novel GlyT1 inhibitors developed

Canadian study assesses involvement of neuroinflammation in healthy aging humans

Agenus and GSK expand license agreement for vaccine adjuvant

FDA clears IND application for phase III trial of melanoma vaccine

Phase III SAR-1118 trial completes enrollment

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

Bayer HealthCare obtains new product approval

Isis launches phase I trial of first-generation antisense drug

Novel candidate schizophrenia therapies patented by Takeda

RaQualia Pharma presents novel sodium channel antagonists

Roche develops new inhibitors of tyrosine-protein kinase BTK

Novel phosphodiesterase 9A inhibitors reported

Celgene completes acquisition

NeuroTherapeutics Pharma divulges new GABA(A) receptor antagonists

Researchers in U.S. design new therapeutics for radiation injury

Benitec Biopharma enters into new licensing agreement

University of Dundee and GSK to target neglected parasitic diseases

Apexigen grants license for APX-004 development in China

Viral Genetics submits pre-IND for Lyme disease treatment

Gene-modified stem cell therapy shows promise to combat HIV infection

Study of AEZS-130 in cancer cachexia begins

Thrombotech clear to test THR-18 in U.S.

Apogenix's phase II trial in glioblastoma multiforme meets primary endpoint

Repligen submits MAA for SecreFlo

Recombinant protein therapy active against HIV in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...